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Abstract 9 
 10 
Carbapenemase-producing Enterobacteriaceae (CPE) contribute significantly to 11 
the global public health threat of antimicrobial resistance. OXA-48, and its 12 
variants, are unique carbapenemases with low level hydrolytic activity toward 13 
carbapenems, but no intrinsic activity against expanded spectrum 14 
cephalosporins. blaOXA-48 is usually located on a plasmid, but may also be 15 
integrated chromosomally, and these genes have progressively disseminated 16 
throughout Europe and the Middle East. Despite the inability of OXA-48-like 17 
carbapenemases to hydrolyse expanded spectrum cephalosporins, pooled 18 
isolates demonstrate high variable resistance to ceftazidime and cefepime, 19 
respectively, likely to represent high rates of extended-spectrum beta-lactamase 20 
(ESBL) co-production. In-vitro data from pooled studies suggests that avibactam 21 
is the most potent beta-lactamase inhibitor when combined with ceftazidime, 22 
cefepime, aztreonam, meropenem or imipenem. Resistance to novel avibactam 23 
combinations such as imipenem/avibactam or aztreonam/avibactam has not yet 24 
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been reported in OXA-48 producers, although only few clinical isolates have 25 
been tested. Although combination therapy is thought to improve chances of 26 
clinical cure and survival in CPE infection, successful outcomes were seen in 27 
~70% of patients with infections caused by OXA-48-producing 28 
Enterobacteriaceae treated with ceftazidime/avibactam monotherapy. A 29 
carbapenem in combination with either amikacin or colistin has achieved 30 
treatment success in a few case reports. Uncertainty remains over the best 31 
treatment options and strategies used to manage these infections. Newly 32 
available antibiotics such as ceftazidime/avibactam show promise, however 33 
recent reports of resistance are concerning. Newer choices of antimicrobial 34 
agents will likely be required to combat this problem.  35 
 36 
Introduction 37 
 38 
Infection due to carbapenemase-producing Enterobacteriaceae (CPE) carries a 39 
significantly high attributable mortality (1). CPE infections are steadily 40 
increasing worldwide and spreading to several countries (2). Moreover, they are 41 
increasing as a proportion of total Enterobacteriaceae infections, with Klebsiella 42 
species being the predominant type (3). OXA-48 is a carbapenemase produced 43 
by a growing number of CPE isolates (4). Plasmid mediated spread has seen it 44 
become a growing problem in the Middle East, North Africa and Europe, 45 
especially the Mediterranean (2, 4). Turkey, the Middle East and North African 46 
countries (mainly Morocco, Tunisia, Egypt and Libya) are considered the 47 
principal reservoirs(5). OXA-181 appears to be unique in having India as its main 48 
reservoir(6). There has been OXA-48-like producing isolates reported in 49 
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Lebanon, the Sultanate of Oman, Saudia Arabia and Kuwait. Recent European 50 
countries include France, Germany, The Netherlands, Italy, Belgium, the United 51 
Kingdom, Ireland, Slovenia, Switzerland and Spain(5).  Although thought to be 52 
almost absent from the Americas, reports have revealed their slow 53 
emergence(3). Australia and New Zealand have both reported sporadic cases(7).  54 
A recent community-acquired urinary tract infection in Algeria has raised 55 
concerns regarding community reservoirs of blaOXA-48(8). Hospital outbreaks 56 
involving OXA-48 producing Enterobacteriaceae have been reported in France, 57 
Germany, Switzerland, the Netherlands and the UK(9). Clonal expansion of 58 
Escherichia coli ST38 carrying a chromosomally integrated blaOXA-48 has also been 59 
documented(10).  The OXA-48 enzyme is an Ambler class D beta-lactamase that 60 
hydrolyses carbapenems but shows very weak activity against extended-61 
spectrum cephalosporins such as cefepime and ceftazidime (2), although isolates 62 
are frequently multi-drug resistant as they combine multiple resistance 63 
mechanisms (11). The gene encoding OXA-48, blaOXA-48, appears to have 64 
originated from Shewanella oneidensis that naturally harbours blaOXA-54, which 65 
has a 92% amino acid sequence homology with blaOXA-48 (12).  66 
 67 
The first identification of OXA-48 producing Enterobacteriaecae was from an 68 
isolate in Turkey in 2001 (13). Shortly thereafter there was an outbreak of OXA-69 
48 producing Klebsiella pneumoniae isolates reported in Istanbul in 2006 (14). 70 
Since its recognition, there have been increasing numbers of reports of OXA-48 71 
producing organisms worldwide, particularly in Europe (2). OXA-48 72 
carbapanemases appear to be uncommon in the US, with the first reported OXA-73 
48 producing isolate identified in 2009 (5, 15). Of 52 identified isolates 74 
 o
n
 August 15, 2018 by UQ Library
http://aac.asm
.org/
D
ow
nloaded from
 
producing OXA-48-like carbapenemases in the US between 2010 and 2015, two 75 
thirds were acquired from outside the US (most frequently India) and the 76 
majority of these involved patients hospitalised whilst overseas (3). OXA-48-like 77 
carbapenemases have also been subsequently described, which include OXA-181 78 
and OXA-163 (2). OXA-181 variant, which differs from OXA-48 by four amino 79 
acid substitutions, is prominent in India and has been associated with other 80 
carbapenemase genes including blaNDM-1 and blaVIM-5 (16). OXA-181 has a similar 81 
pattern of resistance to OXA-48, however OXA-163 hydrolyses extended-82 
spectrum cephalosporins but has only weak activity against carbapenems (2). 83 
Reviewing the treatment efficacy of different antimicrobials is somewhat 84 
challenged due to a paucity of clinical data, often related to inherent difficulties 85 
in laboratory detection of OXA-48 producers due to many of the isolates falling 86 
within the susceptible range for carbapenems.  The challenge of detecting OXA-87 
48 producers is out of the scope of this review and the authors would direct the 88 
readers to other reviews on this topic(6). Currently there is a lack of evidence 89 
and data on treating infections due to OXA-48 producers as recent CPE literature 90 
has focused more on Klebsiella pneumoniae Carbapenemase (KPC)-producers.  91 
 92 
In vitro activity against OXA-48 producers 93 
 94 
OXA-48 producers display a unique in-vitro susceptibility pattern often making 95 
detection difficult with phenotypic methods alone (17). Initial early description 96 
of the dissemination of OXA-48 enzymes were linked to a single IncL/M-type 97 
plasmid not containing any other resistance genes(5).  However, more recently, 98 
epidemiologic studies have demonstrated a strong association with other beta-99 
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lactamase genes, in particular ESBLs (18). OXA-48 is known to hydrolyse 100 
penicillins at a high level, carbapenems at a low level, sparing expanded-101 
spectrum cephalosporins (5). Most current available beta-lactamase inhibitors 102 
(BLI) act only against class A beta-lactamases, remaining ineffective against OXA-103 
48 producers. This has led to a recent surge in research evaluating the in-vitro 104 
effectiveness of new BLI and beta-lactam/BLI combinations. Ceftazidime, 105 
cefepime and aztreonam are not substrates for the OXA-48 beta-lactamase (19, 106 
20). Numerous studies have demonstrated ceftazidime in-vitro efficacy against 107 
OXA-48 producers, in the absence of ESBL co-production (18, 21-23). 108 
Aztreonam, a member of the monobactam class of antibiotics, is stable to 109 
hydrolysis by OXA-48 enzymes and also demonstrates activity against metallo-110 
beta-lactamase (MBL) producing organisms (20, 24). There appears to be 111 
variability in levels of hydrolysis among the different carbapenem 112 
antimicrobials. Carbapenems have been evaluated both in-vitro and in a murine 113 
peritonitis model (20, 25). Doripenem and imipenem, despite testing susceptible 114 
in-vitro, were not efficacious in an in-vivo murine model; ertapenem displayed 115 
little activity in-vivo and in-vitro with an MIC of 3mg/L(20). Moreover, all thirty 116 
OXA-48 isolates characterised in a recent study from the United States were 117 
ertapenem resistant(26). There have been a number of case reports and series 118 
describing treatment failures with carbapenem-containing regimens in the 119 
treatment of OXA-48 producing bacterial infections (4, 27-29). Dual carbapenem 120 
combinations, particularly those with imipenem, have shown synergy in-vitro 121 
against both OXA-48 and KPC producers (30, 31). Although, only some study 122 
isolates (K. pneumoniae but not recombinant E. coli) showed this result and 123 
obtained values close to the cut-off value for defining synergy (30). Interestingly, 124 
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levofloxacin exhibited activity against isogenic OXA-48 strains, but demonstrated 125 
little activity against clinical isolates and failed to suppress infection in an in-vivo 126 
mouse model. Temocillin, a carboxypenicillin used to treat multi-resistant gram-127 
negative organisms, is hydrolysed efficiently by OXA-48 and failed to 128 
demonstrate efficacy in a mouse model (20). Moreover, high level temocillin 129 
resistance has been included in algorithms to aid in OXA-48 recognition (32). 130 
Amdinocillin, an old extended-spectrum penicillin, had in-vitro activity in 48% of 131 
OXA-48 producers in one study when using an extrapolated urinary breakpoint 132 
MIC of 8mg/L(33). Polymyxins, namely colistin, have shown inconsistent and 133 
variable results in in-vitro studies, with many reporting resistance in K. 134 
pneumoniae and E. coli and Enterobacter spp. clinical isolates found to produce 135 
OXA-48 (11, 34). Colistin resistance, likely mediated by alterations in the mgrB 136 
gene, was probably acquired after clonal dissemination of a OXA-48 producing 137 
isolate identified during an outbreak in France in 2014(34). Moreover, the 138 
addition of fosfomycin to colistin was found to be antagonistic against twelve 139 
OXA-48 strains(11). This finding was not statistically significant and it is unclear 140 
whether it is specific to OXA-48 producing K. pneumoniae isolates as there were 141 
no controls used in the study(11). Inconsistencies with regards to in-vitro 142 
susceptibility have been observed with the glycylcycline antibiotic tigecycline, 143 
with a broad range of percentage susceptible isolates identified across different 144 
studies.(35-38)  145 
 146 
Novel beta-lactamase inhibitors  147 
New and established beta-lactamase inhibitors have been extensively studied 148 
evaluating their activity against OXA-48 producing Enterobacteriaceae. OXA-48 149 
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carbapenemases are not effectively inhibited by commonly used BLIs such as 150 
clavulanic acid, tazobactam and sulbactam, which mainly inhibit class A beta-151 
lactamases (21). Avibactam is a diazabicyclooctane (DBO), non-beta-lactam BLI 152 
which may have the ability to inhibit OXA-48 beta-lactamase by forming a stable 153 
covalent complex (21). In one study, it was able to improve the efficacy of 154 
imipenem against OXA-48 producing K. pneumoniae isolates with MIC50 values of 155 
0.016mg/L equating to a 500-fold reduction in MIC50 value.  It also demonstrates 156 
inhibition of class A and C beta-lactamases, making its combination with 157 
cefepime and ceftazidime effective against OXA-48 and ESBL co-producing 158 
organisms, resulting in a 266- and 1000-fold reduction in MIC50 value, 159 
respectively (21, 23). Avibactam has also been added to aztreonam exhibiting 160 
stability to hydrolysis with OXA-48, MBLs, ESBLs, AmpC and KPC (33). 161 
Vaborbactam, a cyclic boronic acid BLI, exhibited no activity against isolates 162 
harbouring blaOXA-48 when combined with meropenem (39). Moreover, 163 
relebactam, another novel BLI, was also unable to show activity when added to 164 
imipenem (23). It is unclear whether the novel DBO BLI, zidebactam is effective 165 
at inhibiting OXA-48 due to it being combined with cefepime in one study, which 166 
is known to be stable to OXA-48 (22). Compound CB-618 is another novel DBO 167 
BLI that has shown promise with in-vitro susceptibility of OXA-48 producers 168 
when combined with meropenem (40). Compound ETX2514 is yet another broad 169 
spectrum DBO with activity against class D beta-lactamases currently in clinical 170 
development in combination with sulbactam for treatment of Acinetobacter 171 
baumannii infection (41). ETX2514 also potently inhibits penicillin-binding 172 
proteins, resulting in intrinsic antibacterial activity that has confounded its 173 
analysis as a novel BLI(42). WCK 234 is a DBO that displays uniquely high 174 
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activity against strains with class D carbapenemases when paired with 175 
imipenem and meropenem in one study. It is a pure BLI and is not known to 176 
display direct antibacterial activity(43). LN-1-255 is a penicillin sulfone 177 
derivative highly effective at inhibiting OXA-48 demonstrated in clinical isolates 178 
and in porin-deficient transformed K. pneumoniae. It has a 33-fold higher 179 
inhibition efficiency than tazobactam, and binds OXA-48 very effectively (44). A 180 
focused fragment library has been set up to examine the in-vitro inhibitory 181 
activity of 49 benzoic acid derivative fragments against OXA-48; as well as to 182 
observe their binding pockets and conformations(45). This approach shows 183 
promise in identifying new molecules for use in building novel BLIs.  184 
 185 
Novel antibiotics 186 
MIC values for ceftazidime-resistant OXA-48 producers, presumably due to co-187 
production of ESBLs, to the new antibiotic ceftolozane/tazobactam are mostly 188 
higher than that found for cefepime/tazobactam (46). In a study of 353 OXA-48 189 
producing isolates, 81.9% of those with a ceftazidime MIC ≤ 4mg/L were 190 
susceptible (EUCAST and CLSI breakpoint ≤1mg/L) to ceftolozane/tazobactam  191 
(C/T) with only 8.1% of those with an MIC ≥4mg/L to ceftazidime reporting 192 
susceptibility to C/T(47). The mechanism for this observation is unknown and 193 
needs further investigation, however explanations include carriage of additional 194 
porin mutations or the possibility of OXA-48 overwhelming tazobactam 195 
rendering it unable to protect ceftolozane against AmpC or ESBL enzymes. The 196 
next generation aminoglycoside plazomicin inhibited all carbapenemase 197 
producing K. pneumoniae isolates (MIC <1mg/L) (48). As with other 198 
aminoglycosides, its in vitro activity is compromised by the presence of 199 
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ribosomal methylases, including ArmA and RmtC. The frequency of these 200 
resistance determinants in OXA-48 producers is uncertain but understood to be 201 
significant(49). Plazomicin appeared to show activity against all CPE isolates 202 
irrespective of species, carbapenemase production or level of resistance to 203 
antibiotics. In addition, synergy was observed at physiologically attainable 204 
concentrations when plazomicin was combined with colistin, meropenem and 205 
fosfomycin (48). A new siderophore cephalosporin, cefiderocol (S-649266), 206 
demonstrated activity against OXA-48 producing strains of K. pneumoniae and 207 
Enterobacter cloacae with MIC values between <0.125-2mg/L (50).  The novel 208 
fluorocycline antibiotic eravacycline has demonstrated in-vitro efficacy against 209 
CPE isolates and carbapenem non-susceptible Acinetobacter baumannii(51, 52).  210 
It has demonstrated non-inferiority to ertapenem in the treatment of 211 
complicated intra-abdominal infection (cIAI) and is awaiting planned clinical 212 
trials assessing its utility in complicated urinary tract infections (cUTI)(53).  213 
Although efficacy in OXA-48-like producers has not been specifically evaluated, 214 
eravacycline remains a possible candidate for future treatment options for 215 
nosocomial and infections due to MDR pathogens. 216 
 217 
Risk factors for OXA-48 colonisation and infection  218 
 219 
Identifying patient risk factors for colonisation and infection is of great 220 
importance in relation to timely institution of effective therapy. In areas where 221 
OXA-48 producing organisms are rarely encountered, recent travel to an area 222 
with a high prevalence provides a significant risk for acquisition(3). Identified 223 
risk factors for colonisation of OXA-48 producing organisms include previous 224 
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intra-abdominal surgery, gastrointestinal or biliary endoscopy, hospitalisation 225 
and intensive care unit admission and antibiotic intake (54). Male gender and 226 
advanced age were identified in another study (55). A multivariate analysis 227 
identified prior administration of a third or fourth generation cephalosporin 228 
(P<0.001) and beta-lactam/BLI combination (P<0.001) as strong risk factors for 229 
colonisation (54). An estimated 10-30% of patients who are colonised with OXA-230 
48 producing CPE will develop infection (56). Another study identified a modest 231 
<10% infection rate in colonised patients (57). Risk factors for infection are 232 
previous inter-hospital transfers, admission to ICU within the previous three 233 
months, invasive procedures during hospitalisation (inc. insertion of central 234 
venous line) and mechanical ventilation (56). In addition, cumulative infection 235 
risk was found to progressively increase during the first 100 days in hospital. 236 
Overall, higher rates of colonisation and/or infection were seen with other multi-237 
drug resistant gram-negative organisms in those with OXA-48 producing CPE.  238 
 239 
 240 
Treatment options 241 
 242 
Ideal antimicrobial therapy for OXA-48-producing Enterobacteriaceae infection 243 
has not been established. A scarcity of clinical data, heterogeneity in pathogen 244 
genotypes assessed, non-randomisation and the retrospective nature of most 245 
studies has contributed to our inability to answer critical questions. Extended-246 
spectrum cephalosporin monotherapy has been used successfully in two case 247 
reports for presumed ESBL negative OXA-48 positive infection, although this is 248 
uncommon (58, 59). Carbapenem monotherapy has been used with varied 249 
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reported rates of success. Meropenem and imipenem were the only 250 
carabapenems used as monotherapy in confirmed OXA-48 producing infections, 251 
with clinical cure and survival rates ranging between 0-66% (4, 27-29). Most 252 
cases were bloodstream infections, often complicating intravenous catheter 253 
placement. Treatment failure of carbapenem monotherapy is likely higher as 254 
many treatment successes involved removal of central venous catheters.  255 
Amikacin has also been used with moderate success with two successful 256 
outcomes in catheter-related bloodstream infection, however a death was 257 
observed in a case of complicated urinary tract infection (27). Its success is likely 258 
also related to the prevalence of alternative mechanisms of resistance in local 259 
isolates. Colistin monotherapy resulted in clinical cure in one case of OXA-48 260 
producing K. pneumoniae bacteraemia (27). Tigecycline has been used as a single 261 
agent therapy in two cases of bacteraemia secondary to a complicated intra-262 
abdominal and soft tissue infection (27). Although surgical intervention was a 263 
key component of their management, both patients had successful outcomes 264 
with tigecycline (27).  Ceftazidime/avibactam as salvage therapy for CPE 265 
infection has shown promise in a case series. In haematology patients with CPE 266 
bacteraemia, 28/38 patients (73.7%) were able to achieve clinical and/or 267 
microbiological cure with ceftazidime/avibactam as monotherapy or in 268 
combination with another antimicrobial, with a delay in therapy being 269 
associated with worse outcomes (60). Of infections caused by OXA-48 producers, 270 
salvage ceftazidime/avibactam produced clinical cure, microbiological cure and 271 
survival to discharge in 8/13 (61.5%), 6/13 (46%) and 5/13(38.5%), 272 
respectively (60). In comparison, those infected with KPC-producing 273 
Enterobacteriaceae yielded 17/23 (74%), 18/23 (78%) and 17/23 (74%) 274 
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respectively. Of all CPE organisms, clinical cure occurred among 68% and 32% of 275 
KPC- and OXA-48 producers, respectively, suggesting an advantage of 276 
ceftazidime/avibactam against this type of carbapenemase(60). Caston et al 277 
reported a higher probability of clinical cure with ceftazidime/avibactam in CPE 278 
bacteraemia, however no significant difference in mortality was noted when 279 
compared to other antimicrobial regimens (61). Although the majority of CPE 280 
isolates included in this study produced an OXA-48 carbapenemase (61.3%), a 281 
significant number produced a Klebsiella pneumoniae Carbapenemase (KPC) 282 
(61). Surveillance data has suggested that resistance to ceftazidime/avibactam 283 
among CPE isolates (excluding those producing Ambler class B beta-lactamases) 284 
is rare, a recent case report documented genetic evidence for MIC elevations 285 
resulting in full non-susceptibility emerging in-vivo through the evolution of 286 
blaCTX-M-14 in a OXA-48-producing K. pneumoniae strain (62).  287 
 288 
Combination therapy in CPE infection is often used and has been posed to offer 289 
reduced mortality and fewer treatment failures (63). A large international 290 
prospective study noted improved survival within combination therapy, but only 291 
in those with high mortality scores (64). In infections involving OXA-48 292 
carbapenemases, dual and triple therapy regimes containing a varied 293 
combination of a carbapenem, aminoglycoside, colistin, tigecycline and 294 
fosfomycin have been used with moderate success. A carbapenem, either 295 
imipenem or meropenem, plus colistin has been used in seven cases involving 296 
catheter-related bloodstream infections, pneumonia and intra-abdominal 297 
infection(4, 27, 29, 65).  Only 3/7 (42.8%) cases treated with this regimen were 298 
able to achieve clinical cure and survived. However, the addition of amikacin to a 299 
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carbapenem, when susceptible to amikacin, seemed to achieve better outcomes 300 
with 3/4 (75%) of OXA-48 bloodstream infections treated with this regimen 301 
surviving (27, 66). Colistin has been used in combination with both tigecycline 302 
and fosfomycin in six and four patients, respectively, in a large retrospective case 303 
series by Navarro-San Francisco et al which documented survival rates of 5/6 304 
(83%) and 3/4 (75%) (27).  Non-carbapenem and non-colistin based dual 305 
therapy with tigecycline and amikacin was used in four patients in the same case 306 
series, reporting survival in 50% (27). Treatment failure and mortality appeared 307 
to be lower among those who received colistin, carbapenem and/or an 308 
aminoglycoside in a combination regimen; although the combination of colistin 309 
and an aminoglycoside was noted to be significantly nephrotoxic (63). An 310 
increase in survival was noted with carbapenem-containing regimens when 311 
meropenem MIC values were <4mg/L(63).  312 
 313 
Conversely, another study documenting an outbreak of OXA-48-producing CPE 314 
reported an increase in mortality associated with imipenem-containing therapy 315 
(4). Lack of adequate detection of OXA-48 producing strains was noted in this 316 
case series attributed to low level resistance to carbapenems and lack of 317 
additional ESBLs, which may have contributed to excess mortality. In 318 
bloodstream infections due to OXA-48 producing Enterobacteriaceae, a non-319 
colistin based combination regimen was found to be an independent risk factor 320 
for death in one study (67). When colistin was used, survival rates were not 321 
significantly different when it was combined with either a carbapenem, 322 
aminoglycoside or broad-spectrum cephalosporin in the setting of 323 
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bacteraemia(27). Interestingly, colistin has been reported as the least effective 324 
when used as monotherapy (67).  325 
 326 
Ceftazidime/avibactam combined with aztreonam in-vitro was able to 327 
demonstrate a synergistic effect against MBL co-producing Enterobacteriaceae in 328 
two reports, being particularly effective against K. pneumoniae isolates, again 329 
highlighting the need to assess for additional mechanisms of carbapenem 330 
resistance in OXA-48 carrying strains (68). Lastly, non-antibiotic options have 331 
been explored with an OXA-48 type carbapenamase producing K. pneumoniae 332 
diabetic foot osteomyelitis acquired in Tunisia being successfully treated with 333 
hyperbaric oxygen therapy alone (69). Overall these observations highlight the 334 
variability and unpredictability of appropriate therapeutic options for this type 335 
of infection.  336 
 337 
Treatment strategies  338 
 339 
An approach to treating infections due to OXA-48 producing Enterbacteriaceae is 340 
undefined and yet to be rigorously studied. Given the unavailability of a single 341 
effective antibiotic, multiple strategies have been proposed and advocated for in 342 
various retrospective studies involving low patient numbers.  Combination 343 
therapy using two or three agents with demonstrated activity against an OXA-48 344 
producing isolate has demonstrated a mortality benefit, when compared with 345 
monotherapy, in a systematic review (63). No difference was noted between dual 346 
and triple therapy regimens. Another study reported greater survival and 347 
microbiological cure of OXA-48 producing Enterbacteriaceae bacteraemia in 348 
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those treated with a single agent; however this was attributed to greater source 349 
control and catheter removal (67). Despite a theoretical benefit, there are no 350 
clinical data to support the notion that combination therapy reduces the 351 
emergence of resistance (63).  352 
 353 
Conclusion  354 
 355 
Patients with infection due to OXA-48 producing Enterobacteriaecae experience 356 
a high mortality, as evidenced by a 30-day mortality rate of 50% in patients with 357 
bacteraemia (27). The progressive spread of blaOXA-48 containing organisms has 358 
been clearly documented in Africa, Middle East and Europe, in particular the 359 
Mediterranean, and is an active threat to the rest of the world (2, 3). OXA-48 has 360 
low-level carbapenem hydrolytic activity and resistance making it difficult to 361 
detect by standard laboratory methods and making treatment failure common. A 362 
number of antibiotics have shown in-vitro activity against OXA-48 producing 363 
Enterobacteriaecae, however this has been largely inconsistent. In addition, 364 
colistin-based regimens are toxic and not well tolerated (63). 365 
Ceftazidime/avibactam perhaps has proven to be most successful from available 366 
in-vitro and clinical data, however reports of resistance are emerging. New BLIs, 367 
paired with appropriate beta-lactams, are being developed which may provide a 368 
solution in the future. New antibiotic choices and randomized controlled trials 369 
are needed in order to inform future decision making and increase the 370 
armamentarium used to treat these difficult infections.  371 
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Tables 681 
Table 1: In-vitro activity against OXA-48 producers 682 
Drug [Reference] Total number of 
isolates tested 
across all 
studies (n) 
MIC50 
(mg/L) 
MIC90 
(mg/L)  
Range 
(mg/L) 
% 
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Ceftazidime(18, 21, 23, 26, 33, 
35, 36, 62, 70, 71) 
674 0.12-
256 
128-
512 
0.06-512 8-40 
Cefepime (18, 21, 22, 26, 46, 
50, 71) 
242 0.25-32 16-512 0.12 to 
>512 
0-46 
Aztreonam (18, 33, 35, 36, 70, 
71) 
  
599 128 128 to 
>512 
<0.015 
to >512 
12.2-27 
Meropenem(18, 26, 35, 36, 38-
40, 50, 62, 70, 72) 
734 0.06 to 
128 
0.25-
256 
2 to 256 0-87.8 
Doripenem (18, 26, 71) 170 >4 0.5 to 
>4 
0.25 to 
>4 
10-83.3 
Ertapenem (18, 26, 35, 36) 373 >1 1 to >8 >1 0-4.1 
Imipenem (18, 23, 26, 35, 36, 
73) 
 
781 0.12-32 8-256 1-256 0-74.8 
Levofloxacin (18, 71) 140 >4 >4 0.03 to 
>4 
0-20.9 
Amdinocillin (33) 14 - - - 43 
Plazomicin (ACHN-490)(74, 75) 19 <0.12 
to 64 
- <0.12 to 
64 
- 
Amikacin (18, 26, 35, 36, 70, 
74) 
628 1-8 2 to 
>64 
0.5 to 
>64 
 
36.7-100 
Gentamicin (74) 19 0.25-
128 
- 0.25 to 
>128 
68 
Colistin (18, 26, 34-36, 38) 
 
520 <0.12-
0.25 
1-128 0.015 to 
128 
75.4-100 
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Tigecycline (18, 26, 35, 36, 38, 
70) 
649 0.25-1 2 0.12-8 36-91 
Fosfomycin (35, 36) 281 - - - 44.8-82 
Piperacillin/Tazobactam (18, 
62, 71) 
155 128 128-
256 
32-256 0 
Ceftazidime/Avibactam (18, 19, 
21, 23, 33, 62, 70) 
705 0.03-1 0.5-
256 
<0.008-
256 
80-100 
Cefepime/Avibactam (21) 26 0.016-
0.12 
0.5 <0.008-
0.5 
100 
Cefepime/Zidebactam (22) 15 <0.03 - - 100 
Cefepime/Tazobactam (46) 25 1-8 - 1-8 80 
Imipenem/Avibactam (21) 26 0.016-
0.5 
0.5 <0.008-2 100 
Imipenem/Relebactam (23) 4 1-8 - 1-8 25 
Aztreonam/Avibactam (24, 33) 71 0.12-
0.25 
0.25-1 0.12-1 100 
Meropenem/Vaborbactam (39, 
72) 
62 16 ≥32 0.12 to 
>32 
0-3.8 
Ceftolozane/Tazobactam (19, 
47) 
21 1 to 
>256 
>256 0.5 to 
>256 
13-50 
Cefiderocol (S-649266) (50) 6 0.25 2 0.125-2 - 
Meropenem/CB-618 (40) 2 0.25-
0.5 
- 0.25-0.5 - 
Labelled “-“ where data not available 683 
 684 
Table 2: Treatment options for OXA-48 producers  685 
Drug regimen Number of patients Type of % Microbiological % Survival at 14-
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[Reference] (n) infection (n) cure 30 days 
Ceftriaxone(27, 59) 
 
2 Endometritis 
(1) 
Bloodstream 
infection (1) 
- 100 
Carbapenem(4, 27-
29) 
10 Pneumonia 
(1) 
Bloodstream 
infection (9) 
- 0-66 
Amikacin(27) 3 Bloodstream 
infection (3) 
- 66 
Colistin(27) 1 Bloodstream 
infection (1) 
- 100 
Tigecycline(27) 2 Bloodstream 
infection (2) 
- 100 
Ceftazidime/Aviba
ctam(60, 61) 
18 Bloodstream 
infection (5) 
25 22.7-70.6 
Ceftazidime + 
Colistin(58) 
1 Catheter-
related 
bloodstream 
infection (1) 
- 100 
Carbapenem+Amik
acin(27, 66) 
4 Bloodstream 
infection (4) 
- 66-100 
Carbapenem+Colist
in(4, 27, 29, 65) 
7 Catheter-
related 
bloodstream 
infection (1) 
Bloodstream 
infection (4) 
- 0-100 
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Pneumonia 
(1) 
Intra-
abdominal 
infection (1) 
 
Colistin+Fosfomyci
n(27) 
4 Bloodstream 
infection (4) 
 
- 75 
Colistin+Amikacin(
27) 
1 Bloodstream 
infection (1) 
 
- 100 
Tigecycline+Amikac
in(27) 
4 Bloodstream 
infection (4) 
- 50 
Tigecycline+Fosfom
ycin(27) 
1 Bloodstream 
infection (1) 
- 100 
Tigecycline+Colisti
n(27) 
6 Bloodstream 
infection (6) 
- 83 
Carbapenem+Amik
acin+Colistin(4) 
2 Catheter-
related 
bloodstream 
infection (1) 
Pneumonia 
(1) 
 
- 50 
Colistin+Amikacin+
Tigecycline(27) 
2 Bloodstream 
infection (2) 
- 50 
Labelled “-“ where data not available686 
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